Implantable Drug Delivery Micropump Patents 2026
Implantable Drug Delivery Micropump Patents 2026
Implantable drug delivery micropumps combine MEMS fabrication, biocompatible materials, and wireless electronics to deliver precise, programmable doses within the body. This dataset spans 2001–2026 across US, EP, AU, IN, WO, and CA jurisdictions.
Miniaturized Active Implants Driving Precision Pharmacotherapy
Implantable drug delivery micropumps are active systems combining a drug reservoir, actuation mechanism, flow control elements, and increasingly onboard sensing and wireless communication. The core challenge—delivering nanoliter-to-microliter volumes at controlled rates over months to years entirely within the body—has driven innovation along parallel actuation tracks including osmotic, piezoelectric, electromagnetic, SMA, and electrophoretic mechanisms.
Foundational system-level claims were established by Medtronic MiniMed, whose early filings created the canonical architecture of reservoir plus driver plus wireless control circuit. Lawrence Livermore National Security introduced microfabricated osmotic engines with shape memory polymer valves enabling zero-power standby operation—a critical constraint for chronic implants operating over multi-year horizons.
The field has evolved from a concentrated duopoly in 2000–2004 toward a fragmented multi-institution phase. Intarcia Therapeutics built a multi-jurisdiction osmotic device portfolio spanning US, EP, AU, WO, and IN, focused entirely on GLP-1 agonist delivery for type 2 diabetes. Academic groups at IIT Kharagpur, Northwestern University, and the American University in Cairo represent the most recent wave of innovation.
Among the 10 patent records retrieved, 5 are currently active or pending—confirming active IP contestation in this dataset. In this dataset, Intarcia Therapeutics holds the largest multi-jurisdictional portfolio with 6 records, while Medtronic MiniMed accounts for 4 records, all now inactive, representing open prior art for new entrants.
Actuation Clusters and Filing Phases in the Micropump Dataset
Patent and literature records in this dataset cluster around four principal actuation mechanisms and span four distinct innovation phases from 2000 to 2026. Active filings are concentrated in osmotic and emerging low-voltage approaches.
Patent Records by Actuation Cluster — Dataset Snapshot
Osmotic engine-driven delivery accounts for the largest share of patent records in this dataset, with 6 records tied to Intarcia Therapeutics and Lawrence Livermore, followed by piezoelectric/diaphragm, electromagnetic/SMA, and phase-change/electrophoretic clusters.
↗ Click bars to exploreFiling Activity by Innovation Phase — Dataset Snapshot
Filing activity in this dataset peaks in the Scale-Up and Wireless Integration Phase (2016–2022), with Intarcia's multi-jurisdiction prosecution concentrated here, while the Emerging Phase (2023–2026) shows the most recent pending filings from academic institutions.
↗ Click bars to exploreKey Application Domains for Implantable Micropump Technology
This dataset documents implantable micropump deployments across six distinct therapeutic and physiological domains, ranging from large-scale diabetes management to precision inner ear and oncology delivery. Each domain presents distinct flow-rate, biocompatibility, and device-size requirements.
Subcutaneous Diabetes Drug Delivery
Medtronic MiniMed's foundational patents (US 2004, EP 2002, CA 2000) established implantable insulin infusion pumps with wireless programmability and septum-refillable reservoirs. Intarcia Therapeutics' multi-jurisdiction portfolio targets continuous GLP-1 agonist (exenatide) delivery achieving therapeutic steady state within 7 days, sustained for ≥3 months. Valveless micropump designs for variable-rate insulin delivery (2016) and integrated pressure-sensor insulin micropumps achieving ±5% delivery accuracy (2014) further densify this application domain.
Metabolic DiseaseMurine Inner Ear Microsystem
A wirelessly controlled 3D-printed microsystem sized at 19×13×3 mm³ was evaluated specifically for murine inner ear drug delivery, with outlet microtubing implanted into the round window membrane niche. Six-month subcutaneous implantation confirmed long-term biocompatibility, addressing the blood-labyrinth barrier that prevents systemic drug administration from reaching inner ear targets. This device represents a high-value localized delivery application documented in a 2021 literature record.
OtologyFischer-344 Rat Intramedullary Implant
A 22 mm diameter × 5 mm PDMS pump embedding NdFeB magnets was wirelessly actuated by an external magnet and successfully implanted in a Fischer-344 rat, connected directly to the intramedullary cavity to modulate fluid flow and stimulate bone cellular activity. Documented in a 2020 literature record, this device replaced the need for transcutaneous tubing required by prior external orthopedic pumps. The approach represents a distinct orthopedic application domain for implantable micropumps.
OrthopedicsTumor Immune Checkpoint Delivery
Implantable optical fibers integrated with drug delivery channels were documented in a 2021 literature record for local immune checkpoint blockade antibody delivery combined with tumor impedance monitoring over multi-week periods. The device enables dose adjustment without systemic toxicity, representing an early-stage oncology application domain in this dataset. This approach targets scenarios where systemic delivery of checkpoint inhibitors produces unacceptable off-target immune effects.
OncologyLeading Patent Assignees in Implantable Micropumps — Dataset Snapshot
In this dataset, Intarcia Therapeutics holds the largest filing portfolio with 6 records across US, EP, AU, WO, and IN jurisdictions, all focused on osmotic subcutaneous delivery for metabolic disease. Medtronic MiniMed accounts for 4 records in retrieved records, all now inactive, representing open prior art for new entrants.
Top Assignees by Filing Count — Implantable Micropump (Dataset Snapshot)
↗ Click bars to exploreIntarcia Therapeutics, Inc.
Intarcia Therapeutics holds 6 patent records in this dataset spanning US (×2, both active), EP (active), AU (×2, one inactive), WO, and IN (inactive), filed between 2011 and 2019. All filings are concentrated on osmotic subcutaneous delivery of GLP-1 agonists for type 2 diabetes, with claims covering rapid establishment of therapeutic steady state within 7 days and sustained delivery for ≥3 months. The US and EP grants remain active, representing the most significant multi-jurisdictional blocking position in this dataset for metabolic disease osmotic devices.
United StatesMedtronic MiniMed, Inc.
Medtronic MiniMed holds 4 records in this dataset across US (×2), EP, and CA jurisdictions, filed between 2000 and 2010, all currently inactive. The filings established the canonical implantable micropump architecture of reservoir plus driver plus wireless control circuit, with applications to insulin infusion and small-molecule insulin mimetic delivery. The inactive status of all Medtronic MiniMed records in this dataset means these foundational architectures are available as open prior art for new entrants.
United StatesNext-Generation Actuation and Control Approaches in Implantable Micropumps
The most recent filings in this dataset (2025–2026) signal a shift toward biocompatible low-voltage actuators, AI-supervised closed-loop controllers, and self-powered delivery architectures that address long-standing constraints of chronic implantable devices.
Ionic Polymer Actuators Replace Lead-Containing PZT
The IIT Kharagpur filing (IN, 2025, pending) explicitly positions Nafion ionic polymer membranes embedded with nanomaterials as a replacement for lead-containing PZT diaphragms. This addresses both the high driving voltage requirements (documented up to 100 V for PZT) and lead toxicity concerns that have historically limited implantable piezoelectric pumps. The direction aligns with growing regulatory pressure on lead-based materials in implantable devices.
AI-Supervised Closed-Loop Controllers for Pain Management
The Graphic Era Hill University patent (IN, 2026, pending) describes a controller with non-volatile therapy parameter storage, authenticated telemetry sessions, integrated flow sensing with per-actuation volume computation, and alarm thresholds. This closed-loop architecture mirrors the artificial pancreas paradigm applied to generalized pain management. The design includes catheter delivery, flow sensing, and an authenticated external programmer for opioid or analgesic infusion with basal and bolus delivery profiles.
Osmotic Engine vs. Piezoelectric Diaphragm Micropump Approaches
Click any row to explore further.
| Dimension | Osmotic Engine (Intarcia / Lawrence Livermore) | Piezoelectric Diaphragm MEMS |
|---|---|---|
| Actuation Mechanism | Osmotic pressure differential across semipermeable membrane; zero active electronics in pumping element | PZT or ionic polymer diaphragm deflection; requires driving voltage up to 100 V for PZT |
| Flow Rate Range | Continuous, months-to-years sustained delivery at subcutaneous peptide therapeutic rates | Up to 74 µL/min max flow rate demonstrated in 5×5 mm² silicon micropump (2021 literature) |
| Power Requirement | Zero power in standby; passive osmotic engine requires no battery for pumping element | Active power required; high voltage for PZT; ionic polymer alternatives target low-voltage operation |
| Key Application | GLP-1 agonist (exenatide) delivery for type 2 diabetes; metabolic disease subcutaneous delivery | Insulin delivery, artificial pancreas integration; pressure sensor enables ±5% delivery accuracy |
| Biocompatibility Concern | Semipermeable membrane material; Parylene-C coating documented for gallium variant | Lead toxicity of PZT for in vivo use; Nafion ionic polymer proposed as lead-free alternative (IIT Kharagpur, 2025) |
| IP Status in Dataset | Intarcia US and EP grants active; Lawrence Livermore records inactive (open prior art) | IIT Kharagpur ionic polymer filing pending (IN, 2025); earlier silicon micropump literature not patented in dataset |
| Safety Feature | Solidified gallium as zero-power normally-closed valve preventing backflow (phase-change variant) | Piezoresistive pressure gauges in pumping chamber and outlet for failure detection (2014 literature) |
Frequently Asked Questions: Implantable Drug Delivery Micropump Patents
In this dataset, Intarcia Therapeutics holds 6 patent records spanning US (×2, both active), EP (active), AU (×2, one inactive), WO, and IN (inactive), representing the largest multi-jurisdictional portfolio. All filings are concentrated on osmotic subcutaneous delivery of GLP-1 agonists for type 2 diabetes.
No. All 4 Medtronic MiniMed records in this dataset across US (×2), EP, and CA jurisdictions are currently inactive, indicating expired or lapsed protection. This means the foundational architectures—reservoir plus driver plus wireless control circuit—are available as open prior art for new entrants.
The primary biocompatibility concern is lead toxicity associated with PZT (lead zirconate titanate) diaphragms, which also require driving voltages up to 100 V. The IIT Kharagpur filing (IN, 2025, pending) proposes Nafion ionic polymer membranes embedded with nanomaterials as a biocompatible, low-voltage alternative to address both constraints.
A 5×5 mm² piezoelectric silicon micropump demonstrated 74 µL/min maximum flow rate, 51 kPa blocking pressure, and 12.5 kPa backpressure capability (2021 literature). A gallium phase-change peristaltic micropump (7×13×1 mm, <100 mm³) demonstrated 18–104 nL/min ultra-low flow rates suitable for chronic neurological or pain management delivery.
India (IN) accounts for 3 recent filings in this dataset from academic institutions: IIT Kharagpur (2025, pending) for ionic polymer micropumps, Graphic Era Hill University (2026, pending) for AI-supervised pain management devices, and Amrita Vishwa Vidyapeetham (2008) for a dual microcontroller infusion device. The dataset shows no CN or KR filings, though the content notes this likely reflects search scope rather than absence of activity.
Intarcia's US patent (2019, active) claims continuous GLP-1 agonist delivery achieving therapeutic steady state within 7 days, sustained for ≥3 months. The European counterpart (EP, 2012, active) establishes pan-jurisdictional coverage of the same osmotic device platform, and the portfolio spans US, EP, AU, WO, and IN jurisdictions filed between 2011 and 2019.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.